Anti-phosphatidylserine/prothrombin Complex Antibodies (aps/pt) Increase the Risk for Thrombosis Based on Lupus Anticoagulant Positivity

Yuncong Zhang,Yang Su,Han Guo,Lu Wang,Aiwei Li,Chanjuan Wang,Jie Zhang,Rui Qiao
DOI: https://doi.org/10.1016/j.clinbiochem.2022.12.007
IF: 3.625
2023-01-01
Clinical Biochemistry
Abstract:Background: Lupus anticoagulants (LA) increase the risk of thrombotic and obstetric events in patients with antiphospholipid syndrome than in those with other antiphospholipid antibodies. Anti-phosphatidylserine/ prothrombin (aPS/PT) complex antibodies are thought to cause LA positivity. Therefore, we aimed to explore whether aPS/PT antibodies could prolong phospholipid (PL)-dependent clotting time and increase the risk of thrombosis or pregnancy complications based on LA positivity. Methods: We recruited 222 patients with positive LA and estimated their aPS/PT, anticardiolipin (aCL), anti-82glycoprotein I (a82GPI), and anti-82GPI domain I (anti-D1) antibody (IgM and IgG) titers and PL-dependent clotting time. Results: PT was longer in aPS/PT IgG-positive patients than in aPS/PT IgM-negative patients (P < 0.001), while there was no significant difference between aPS/PT IgM-positive and IgM-negative patients (P = 0.100). Both SCT-S and dRVVT-S were prolonged in aPS/PT (IgG and IgM)-positive patients compared to aPS/PT-negative patients (P < 0.001, P = 0.010, P < 0.001, P = 0.002, respectively). Similarly, the associations between aPS/ PT IgG or IgM antibody titers and SCT-S or dRVVT-S were significant. SCT-C and dRVVT-C did not show any significant differences. The incidence of thrombosis in the aPS/PT IgG-positive group was much higher than that in the IgG-negative group (P = 0.012). Likewise, the incidence of thrombosis was higher in the anti-D1- and aPS/ PT IgG-positive patients than in the negative controls (40 % vs 14.3 %, x2 = 3.934, P = 0.047). Furthermore, the aPS/PT IgG-positive group showed the strongest association with thrombosis [OR 2.584, 95 % CI (1.213, 5.505)]. Conclusion: The aPS/PT antibodies prolonged PL-dependent clotting time, especially SCT-S and dRVVT-S. In addition, the presence of aPS/PT IgG antibodies increased the risk of thrombosis in LA positivity.
What problem does this paper attempt to address?